Literature DB >> 24355643

Updated treatment algorithm of pulmonary arterial hypertension.

Nazzareno Galiè1, Paul A Corris2, Adaani Frost3, Reda E Girgis4, John Granton5, Zhi Cheng Jing6, Walter Klepetko7, Michael D McGoon8, Vallerie V McLaughlin9, Ioana R Preston10, Lewis J Rubin11, Julio Sandoval12, Werner Seeger13, Anne Keogh14.   

Abstract

The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple and in some ways conflicting. The treatment algorithm usually includes different types of recommendations with varying degrees of scientific evidence. In addition, the algorithm is required to be comprehensive but not too complex, informative yet simple and straightforward. The type of information in the treatment algorithm are heterogeneous including clinical, hemodynamic, medical, interventional, pharmacological and regulatory recommendations. Stakeholders (or users) including physicians from various specialties and with variable expertise in PAH, nurses, patients and patients' associations, healthcare providers, regulatory agencies and industry are often interested in the PAH treatment algorithm for different reasons. These are the considerable challenges faced when proposing appropriate updates to the current evidence-based treatment algorithm.The current treatment algorithm may be divided into 3 main areas: 1) general measures, supportive therapy, referral strategy, acute vasoreactivity testing and chronic treatment with calcium channel blockers; 2) initial therapy with approved PAH drugs; and 3) clinical response to the initial therapy, combination therapy, balloon atrial septostomy, and lung transplantation. All three sections will be revisited highlighting information newly available in the past 5 years and proposing updates where appropriate. The European Society of Cardiology grades of recommendation and levels of evidence will be adopted to rank the proposed treatments.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-min walk distance; 6MWD; APAH; BAS; CCB; ERA; PAH; PVR; RCT; WHO-FC; World Health Organization Functional Class; associated pulmonary arterial hypertension; balloon atrial septostomy; calcium channel blocker; endothelin receptor antagonist; endothelin receptor antagonists; guanylate cyclase stimulators; hypertension, pulmonary; lung transplantation; phosphodiesterase type-5 inhibitors; prostanoids; pulmonary; pulmonary arterial hypertension; pulmonary vascular resistance; randomized controlled trials

Mesh:

Substances:

Year:  2013        PMID: 24355643     DOI: 10.1016/j.jacc.2013.10.031

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  200 in total

1.  ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine.

Authors:  Gaëtane C Michaud; Colleen L Channick; Chad R Marion; Robert M Tighe; James A Town; Andrew M Luks; Jeremy B Richards; Sucharita Kher; Prerna Mota; Gina Hong; Natalie E West; Craig Rackley; Luke Neilans; Josanna Rodriguez-Lopez; Hilary DuBrock; Cassie C Kennedy; Diana J Kelm; Carey C Thomson
Journal:  Ann Am Thorac Soc       Date:  2015-09

Review 2.  Medical therapies for pulmonary arterial hypertension.

Authors:  Tomas Pulido; Nayeli Zayas; Maitane Alonso de Mendieta; Karen Plascencia; Jennifer Escobar
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 3.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

4.  Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension.

Authors:  Jenny Y Chen; Megan Griffiths; Jun Yang; Melanie K Nies; Rachel L Damico; Catherine E Simpson; R Dhananjay Vaidya; Stephanie Brandal; D Dunbar Ivy; Eric D Austin; William C Nichols; Michael W Pauciulo; Katie Lutz; Erika B Rosenzweig; Russel Hirsch; Delphine Yung; Allen D Everett
Journal:  J Pediatr       Date:  2020-08       Impact factor: 4.406

5.  Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular Disease.

Authors:  Evgeny A Zemskov; Qing Lu; Wojciech Ornatowski; Christina N Klinger; Ankit A Desai; Emin Maltepe; Jason X-J Yuan; Ting Wang; Jeffrey R Fineman; Stephen M Black
Journal:  Antioxid Redox Signal       Date:  2019-03-19       Impact factor: 8.401

Review 6.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

7.  Metabolism and Redox in Pulmonary Vascular Physiology and Pathophysiology.

Authors:  Norah Alruwaili; Sharath Kandhi; Dong Sun; Michael S Wolin
Journal:  Antioxid Redox Signal       Date:  2018-12-21       Impact factor: 8.401

Review 8.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

9.  Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.

Authors:  Ruben de Kanter; Patricia N Sidharta; Stéphane Delahaye; Carmela Gnerre; Jerome Segrestaa; Stephan Buchmann; Christopher Kohl; Alexander Treiber
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

10.  Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?

Authors:  Muhammad Shahzeb Khan; Muhammad Shariq Usman; Tariq Jamal Siddiqi; Safi U Khan; M Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Richard A Krasuski; Raymond L Benza; Jonathan D Rich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.